Age-Related Macular Degeneration Market Size
The Age-Related Macular Degeneration Market is estimated to reach USD 16.40 Billion in 2025 and is projected to grow to USD 30.03 Billion by 2035, registering steady growth at a CAGR of 6.3% during the forecast period from 2026 to 2035.
The global age-related macular degeneration (AMD) treatment market is primarily driven by rising prevalence. Moreover, due to advancements in diagnostics, the diagnosis rate has significantly increased, along with which, the treatment rate has seen positive growth.
Moreover, several companies are actively engaged in product development activities with novel mechanisms of action. These novel products have the potential to open a new therapeutic class for age-related macular degeneration (AMD) treatment. VEGF inhibitors are such products that have revolutionized the AMD treatment landscape.
North America has the highest market share due to the availability of advanced therapies and a greater portion of the revenue generated by market players.
Age-Related Macular Degeneration Market Executive Summary
For more details on this report -Request for Sample
Age-Related Macular Degeneration Market Key Takeaways
- Wet AMD remains a major revenue-generating segment, supported by continued demand for anti-VEGF therapies and recurring treatment requirements.
- Dry AMD and geographic atrophy are becoming major growth opportunities, driven by the emergence of therapies targeting disease progression rather than only managing symptoms.
- Long-acting treatment technologies are gaining importance as pharmaceutical companies seek to reduce injection frequency, improve patient adherence and lower the overall treatment burden.
- Complement-pathway therapies are expanding the AMD treatment landscape, particularly for geographic atrophy, creating new opportunities beyond conventional anti-VEGF treatment.
- Biosimilar adoption is increasing competitive pressure in established anti-VEGF markets by offering potentially lower-cost alternatives and encouraging manufacturers to differentiate through efficacy, durability and convenience.
- Drug-delivery innovation is becoming a key competitive factor, with sustained-release formulations, implant-based systems and other extended-duration approaches being developed to address frequent treatment requirements.
- Retinal imaging is becoming increasingly important, with OCT, OCT angiography and automated image analysis supporting diagnosis, disease monitoring and treatment decisions.
- AI-assisted retinal screening represents an emerging opportunity, particularly for early disease detection, image interpretation, patient prioritization and remote monitoring.
- Population aging remains a fundamental market driver, particularly in North America, Europe and Japan, where the proportion of older adults is increasing.
- Asia-Pacific offers significant expansion potential due to its large aging population, improving ophthalmology infrastructure, increasing disease awareness and expanding access to specialized retinal care.
- Treatment burden remains a major unmet need, creating opportunities for therapies that extend dosing intervals and reduce the frequency of clinic visits and intravitreal injections.
- The competitive landscape is shifting from molecule-based competition toward broader treatment-platform competition, including drug durability, delivery systems, diagnostic integration, patient support and real-world outcomes.
- The AMD market is expanding beyond pharmaceuticals, creating opportunities across retinal diagnostics, imaging, digital monitoring, specialty clinics and healthcare-support technologies.
- Pipeline innovation is increasingly diversified, covering complement inhibition, gene therapy, cell therapy, neuroprotection, RNA-based approaches and combination therapies.
Age-Related Macular Degeneration Market Dynamics: Drivers & Restraints
The rising prevalence of age-related macular degeneration (AMD) is driving the market growth
Age-related macular degeneration is a condition that affects people as they age. As the global population ages, the incidence and overall prevalence of AMD are expected to rise. For instance, according to the World Health Organization (WHO), by 2030, one in every six people in the world will be 60 or older. At this time, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the global population aged 60 and up will double, and reach 2.1 billion. The number of people aged 80 and older is predicted to triple between 2020 and 2050, reaching 426 million.
According to a study by Wan Ling Wong et al, published in the Lancet Glob Health journal, the population with age-related macular degeneration (AMD) is expected to reach 288 million by 2040 from 196 million in 2020. This drastic increase in the prevalent population increases the demand for advanced therapies for AMD, which in turn improves the R&D activities, increases product launches, and market growth.
The high cost of treatment may restrain the market growth
At present, anti-VEGF drugs have established themselves as a standard of care for the AMD population. However, their high cost can pose a significant economic burden to the patients. For instance, one Eylea injection can cost up to US$ 2,000 per patient, and the Eylea HD injection can cost up to US$ 2,600 per patient. The patient needs these injections initially every 4 weeks, then 4-12 weekly thereafter, based on the condition and its severity. Patients with partial or no insurance coverage may not be able to afford the treatment, which can lead to lower adoption and market hindrance.
Age-Related Macular Degeneration Market Scope
| Metrics | Details | |
| CAGR | 6.3% | |
| Market Size Available for Years | 2025-2035 | |
| Estimation Forecast Period | 2026-2035 | |
| Revenue Units | Value (US$ Mn) | |
| Segments Covered | Type | Dry AMD, Wet AMD |
| Treatment | Anti-VEGF Drugs, AREDS2 Supplements, Photodynamic Therapy, Others | |
| Patient Type | Male, Female | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
Age-Related Macular Degeneration Market Trends & Insights
Long-Acting Therapies Are Reducing the Treatment Burden
The AMD treatment landscape is shifting toward therapies that can maintain disease control for longer periods and reduce the frequency of intravitreal administration. Longer treatment intervals can improve patient convenience, reduce clinic visits and potentially improve adherence, making durability an important competitive factor.
Wet AMD Continues to Drive High-Value Treatment Demand
Neovascular or wet AMD remains a major commercial segment because anti-VEGF therapies have become a central treatment approach for controlling abnormal blood-vessel growth and leakage. The continuing need for repeated treatment supports recurring demand for ophthalmic medicines.
Geographic Atrophy Is Creating a New Treatment Opportunity
The development of therapies targeting geographic atrophy is expanding the addressable treatment landscape for dry AMD. Complement-pathway therapies have introduced a new treatment category for patients with advanced geographic atrophy, while improving functional vision outcomes remains an important area for further innovation.
Complement Inhibition Is Reshaping Dry AMD Treatment
Complement-system modulation has become an important area of AMD research. The emergence of complement inhibitors demonstrates the industry's movement beyond supportive management toward therapies intended to slow progression of geographic atrophy.
Anti-VEGF Biosimilars Are Increasing Pricing Pressure
The expansion of biosimilar and alternative anti-VEGF therapies can increase treatment accessibility while creating pricing pressure for established branded products. Manufacturers are increasingly competing through treatment durability, delivery systems, clinical outcomes and patient convenience.
Drug Delivery Innovation Is Becoming a Major Differentiator
Treatment innovation is increasingly focused not only on the drug molecule but also on how frequently and conveniently it can be administered. Sustained-release systems, refillable ocular implants and other extended-delivery approaches are being developed to reduce repeated injections.
Early Diagnosis Is Expanding the Treatable Patient Pool
Improved retinal imaging and greater awareness of AMD are supporting earlier identification of disease. Earlier diagnosis can create opportunities for monitoring and intervention before irreversible visual impairment becomes extensive.
Aging Populations Are Creating Structural Demand
The increasing proportion of older adults is one of the most important long-term drivers of AMD prevalence. Population aging is particularly relevant in developed markets and increasingly important in Asia-Pacific as healthcare access and life expectancy improve.
AI-Assisted Retinal Imaging Is Supporting Earlier Detection
Artificial intelligence and automated image-analysis technologies are increasingly being explored for retinal screening, lesion identification, disease classification and monitoring. Wider adoption could improve screening efficiency and support earlier referral to retinal specialists.
Home-Based Monitoring Could Change AMD Follow-Up
Remote vision monitoring and home-based retinal assessment technologies could allow clinicians to identify disease changes between conventional appointments. This creates opportunities for earlier intervention while potentially reducing unnecessary clinic visits.
Age-Related Macular Degeneration Market Segment Analysis
The global age-related macular degeneration market is segmented based on type, treatment, patient type, and region.
The anti-VEGF drugs in the type segment accounted for 78.5% of the market share in 2024 in the global age-related macular degeneration market
Anti-vascular endothelial growth factor (VEGF) drugs have evolved as a promising therapeutic agent for the treatment of age-related macular degeneration, especially for wet age-related macular degeneration. These are intravitreal injections that slow down the disease progression by blocking the activity of VEGF and reducing the formation of abnormal blood vessels.
There are several approved anti-VEGF drugs currently revolutionizing the treatment of age-related macular degeneration. The majority of these drugs are monoclonal antibodies and include Ranibizumab, Brolucizumab, Faricimab, Bevacizumab, etc. They are effective in reducing the newly forming vasculature during the early stages of age-related macular degeneration, thereby delaying the progression of central vision loss. This direct and selective inhibition of neovascularization is the major reason behind their therapeutic efficacy and increased adoption rate.
Moreover, these drugs are expensive, and most of them are patent-protected. Manufacturers generate most of their revenue from sales of these products, which is another major contributing factor to their greater market share.
The novel therapies are also focused on this target mechanism, which reflects the segment’s highest growth rate in the forecast period. For instance, AbbVie and REGENXBIO Inc. are combinedly to develop a novel one-time gene therapy that targets the VEGF pathway for the treatment of wet age-related macular degeneration. On October 21, 2024, REGENXBIO Inc. announced positive results of phase 2 clinical trials. The data were presented to the American Academy of Ophthalmology (AAO), and the results suggest that ABBV-RGX-314 has the potential to revolutionize the treatment paradigm of wet age-related macular degeneration.
Age-Related Macular Degeneration Market Geographical Analysis
North America dominated the age-related macular degeneration market with the highest share of 48.4% in 2024
North America region is expected to hold the largest market share over the forecast period. North America is well known for its advanced healthcare industry. The higher expenditure on healthcare and rising awareness among people, the advancement of technologies for Age-Related Macular Degeneration (AMD) treatment, and rising prevalence are the major contributing factors for the region’s dominance.
For instance, in 2022, an epidemiology study published in the JAMA Ophthalmology Journal stated that the prevalent cases (above 40 years of age) of age-related macular degeneration in the U.S. were 18.34 million in 2019. For instance, according to the BrightFocus Foundation, nearly 20 million people in the U.S. are living with some form of age-related macular degeneration. This surge in patient population is expected to create a higher demand for advanced therapeutics. North America, especially the U.S., is at the forefront of developing these advanced therapeutics.
Moreover, the market players generate the majority of their product revenue from the North America region, especially from the U.S. For instance, in 2023, F. Hoffmann-La Roche Ltd generated approximately 4.4 billion USD for Vabysmo, an anti-VEGF therapy indicated in AMD. The company has generated approximately 75% of its revenue from the United States. Moreover, Regeneron Pharmaceuticals Inc. has generated approximately 62.5% of the 9.5 USD billion revenue of Eylea from the United States. This reflects the region’s dominating share in the global age-related macular degeneration (AMD) treatment market.
Age-Related Macular Degeneration Market Product-Level Competitive Analysis
Aflibercept-Based Therapies
A major anti-VEGF category used for retinal vascular diseases, including wet AMD. Product differentiation increasingly depends on dosing interval, formulation and delivery efficiency.
Ranibizumab-Based Therapies
An established anti-VEGF treatment class with continued relevance in retinal disease management and ongoing competition from alternative products and delivery approaches.
Brolucizumab
Represents another anti-VEGF approach and demonstrates the industry's efforts to improve treatment durability and reduce injection burden.
Faricimab
A newer mechanism combining VEGF-A inhibition with Ang-2 pathway targeting, providing an example of how companies are pursuing differentiated approaches beyond conventional single-pathway VEGF inhibition.
Pegcetacoplan
A complement C3 inhibitor developed for geographic atrophy and an important example of the transition toward disease-modifying treatment for advanced dry AMD.
Avacincaptad Pegol
A complement C5 inhibitor developed for geographic atrophy and another important development in the expansion of treatment options for dry AMD.
Age-Related Macular Degeneration Market Drug Delivery Technology Analysis
Intravitreal Injection
The established delivery method for many AMD therapies, but repeated administration creates treatment burden.
Sustained-Release Delivery
Designed to maintain therapeutic drug levels for longer periods and reduce administration frequency.
Implant-Based Delivery
Implantable systems can provide extended drug release and may reduce the frequency of clinic-based injections.
Gene-Based Delivery
Gene therapies are being investigated as a potential approach to producing sustained therapeutic effects from a single administration.
Home Monitoring + Drug Delivery
The combination of remote disease monitoring and longer-acting therapies could create a more patient-centered AMD management model.
Age-Related Macular Degeneration Market Major Players
The major players in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Biocon, Samsung Bioepis, Bausch + Lomb, Alcon Inc., and Nature Made, among others.
Key Development in the Age-Related Macular Degeneration Market
- July 2026: Regeneron Pharmaceuticals reported strong growth for EYLEA HD, with U.S. sales increasing 52% year over year to US$596 million in Q2 2026. The company continues expanding EYLEA HD's role in wet AMD treatment.
- April 2026: Regeneron Pharmaceuticals received FDA approval to extend EYLEA HD dosing intervals up to every 20 weeks (five months) for eligible patients with wet AMD and diabetic macular edema who have achieved a successful response after one year.
- April 2026: F. Hoffmann-La Roche continued expanding the global uptake of Vabysmo, which generated approximately CHF 1.024 billion in Q1 2026 sales, representing 13% year-over-year growth.
- April 2026: Roche continued advancing its ophthalmology pipeline, including Vabysmo and Susvimo, while pursuing additional regulatory opportunities and indications across retinal diseases.
- July 2026: Samsung Bioepis expanded commercialization of OPUVIZ (aflibercept), an Eylea biosimilar, including its European rollout and additional international market expansion.
- July 2026: Samsung Bioepis relaunched BYOOVIZ (ranibizumab-nuna) in the United States in partnership with Harrow, strengthening competition in the ophthalmic biosimilar segment.
- July 2026: Samsung Bioepis presented interim results from a large-scale post-marketing surveillance study of SB11 (BYOOVIZ/AMELIVU), supporting continued real-world evidence generation for ranibizumab biosimilar use.
- July 2026: Biocon Biologics continued expanding its ophthalmology biosimilar portfolio following the commercial rollout of Yesafili (aflibercept) in international markets.
- July 2026: Samsung Bioepis entered an agreement with Teva to commercialize OPUVIZ (aflibercept) in Canada, further expanding geographic access to an Eylea biosimilar.
- June 2026: Samsung Bioepis announced positive preliminary Phase 1 and Phase 3 data for SB27 while continuing to expand its broader biosimilar development pipeline.
Why Choose DataM?
Technological Innovations: DataM evaluates advances in anti-VEGF therapies, long-acting formulations, sustained-release delivery, complement inhibitors, gene therapy, cell-based approaches, AI-assisted retinal imaging, OCT-based monitoring and emerging disease-modifying technologies.
Product Performance & Market Positioning: The report evaluates AMD therapies based on visual outcomes, treatment durability, injection frequency, safety, mechanism of action, dosing interval, delivery technology, patient adherence, reimbursement and cost-effectiveness.
Real-World Evidence: DataM connects market developments with clinical applications across wet AMD, dry AMD and geographic atrophy while assessing treatment patterns across hospitals, specialty eye centers and retinal-care networks.
Market Updates & Industry Changes: The report tracks regulatory approvals, clinical trials, product launches, biosimilar developments, complement-targeted therapies, long-acting formulations, drug-delivery innovations, diagnostic technologies and strategic pharmaceutical collaborations.
Competitive Strategies: DataM analyzes how leading companies strengthen their positions through novel mechanisms, extended-duration therapies, proprietary delivery systems, biosimilar portfolios, licensing agreements, clinical partnerships, acquisitions and geographic expansion.
Pricing & Market Access: DataM evaluates pricing according to drug class, treatment frequency, formulation, delivery method, clinical benefit, reimbursement environment, healthcare setting and competitive pressure from biosimilars.
Market Entry & Expansion: DataM identifies opportunities created by population aging, rising AMD prevalence, improved diagnosis, geographic-atrophy treatments, long-acting therapies, retinal monitoring and expanding ophthalmology infrastructure. The report outlines strategies involving pharmaceutical partnerships, specialty-care networks, local distribution, regulatory alignment and expansion across Asia-Pacific markets.
Target Audience
- Pharmaceutical Companies -Drug and pipeline strategy.
- Ophthalmology Companies -Product development and positioning.
- Retinal Care Providers -Treatment and technology planning.
- Investors -Market and competitive intelligence.
- Diagnostic Companies -Retinal imaging and monitoring opportunities.
- Healthcare Providers -AMD treatment and market insights.
